New Drug Research and Development

Persistence is the key to success. After 20 years of hard work, Charsire has developed the world’s leading patented technology platform of “Multi-Glycan Complex, MGC”. It characterized by short development time and low R&D costs, which greatly shortens the time for new drug development and will make great contributions in the medical field.

New Medicine Research and Development

Persistence is the key to success. After 20 years of hard work, CHARSIRE has developed the world’s leading patented technology platform of “Multiple Carbohydrate Complex MGC”. It has the characteristics of short research and development time and low costs, which greatly shortens the time for new drug development and will make great contributions in the medical field.

Charsire innovates the development of new topical medication and and masters a numbers of R&D achievements. Charsire obtained invention patents in 16 countries including the United States, the European Union, and China. Various research breakthroughs and major discoveries are made.

The Phase II trial of the US FDA for new dementia drug BAC has completed. The Phase III clinical trial is underway, which will result in explosive growth.

New Dementia Drug BAC

Charsire’s new drug for Alzheimer’s disease and vascular dementia has completed the Phase II clinical trial approved by the US FDA and successfully found the drug response group, and will expand the Phase III trial to confirm the efficacy.

More

New Diabetic Ulcer Wound Drug CSTC1

The new drug for diabetic ulcer wounds has completed the Phase II clinical trial approved by the US FDA and obtained the approval of Taiwan’s Class II medical device.

More

New Radiodermatitis Drug ACA

Charsire’s new radiodermatitis drug ACA has completed the Phase I clinical trial, which can effectively reduce side effects such as pain and skin reaction during radiotherapy, and improve the treatment quality and effect of radiotherapy patients.

More

Intellectual Property

專利資訊

YearPatent Description
2022The United States- utility patent for the treatment of breast cancer
2021The United States- utility patent for relief of cancer pain and/or skin inflammation caused by radiotherapy
2021Canada- utility patent for the synergistic effect of chemotherapeutic drugs for brain diseases and breast cancer
2021Republic of China (Taiwan)- utility patent for relief of cancer pain and/or skin inflammation caused by radiotherapy
2020Singapore- utility patent for the synergistic effect of diabetic ulcer wounds, brain disease, and breast cancer chemotherapy drugs
2020The United States- utility patent for brain disease
2018Japan- utility patent for the synergistic effect of diabetic ulcer wounds, brain disease, and breast cancer chemotherapy drugs
2018Republic of China (Taiwan)- utility patent for the synergistic effect of diabetic ulcer wounds, brain disease, and breast cancer chemotherapy drugs
2018Korea- utility patent for the synergistic effect of chemotherapeutic drugs to reduce the side effects of chemotherapy
2018Russia- utility patent for brain disease
2018Australia, invention patents for diabetic ulcer wounds, brain disease, breast cancer and the addition of chemotherapy drugs.
2017India, Invention Patents for Skin Medicine.
2013Korea, invention patent of skin medicine.
2013Korea, invention patent of skin medicine.
2013Malaysia, Skin Medicine Invention Patent.
2013Korea, invention patent of skin medicine.
2012Canada, Skin Medicine Invention Patent.
2011Japan, Invention Patent for Skin Medicine.
2011Republic of China, invention patent of skin medicine.
2010Australia, Skin Medicine Invention Patent.
2008Singapore, the invention patent of skin medicine.
2008Mainland China, invention patent of skin medicine.
2007European Union, skin medicine invention patent.
2007U.S., skin medicine invention patent.
2006In the United States, the first medical invention patent was officially obtained.